The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro

International Journal of Radiation Biology

Volumn 84, Issue 8, 2008, Pages 643-657

  Nitsche, Mirko ^a   Christiansen, Hans ^a   Hermann, Robert M ^a   Lücke, Eva Maria ^b   Peters, Kerstin ^a   Rave Fränk, Margret ^a   Schmidberger, H ^c   Pradier, Olivier ^d  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d BREST UNIVERSITY HOSPITAL   (France)

Author keywords

Fludarabine; Gemcitabine; Head and neck cancer; Nucleoside analogues; Radiation sensitizing

Indexed keywords

FLUDARABINE PHOSPHATE; GEMCITABINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION; RADIATION DOSE; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; HUMANS; RADIATION-SENSITIZING AGENTS; VIDARABINE PHOSPHATE;

EID: 48249088499     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000802241754     Document Type: Article

References (65)

1. Aguilar-Ponce J, Granados-Garcia M, Villavicencio V, Poitevin-Chacon A, Green D, Duenas-Gonzales A, Herrera-Gomez A, Luna-Ortiz K, Alvarado A, Martinez-Said H, Castillo-Henkel C, Segura-Pacheco B, De la Garza J. 2004. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Annals of Oncology 15(2):301-306.
2. Barrueco JR, Jacobson DM, Chang CH, Brockman RW, Sirotnak FM. 1987. Proposed mechanism of therapeutic selectivity of 9-ß-D-Arabinofuranosyl-2- fluoroadenine against murine leukaemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumour cells. Cancer Research 47:700-706.
3. Benasso M, Corvo R, Ponzanelli A, Sanguineti G, Ricci I, Pallestrini E, Santelli A, Vitale V, Rosso R. 2004. Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous head and neck carcinoma of the head and neck. Annals of Oncology 15(4):646-652.
4. Brockman RW, Cheng YC, Schabel FM, Montgomery JA. 1980. Metabolism and chemotherapeutic activity of 9-ß-D-arabinofuranosyl-2-Fuoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Research 40:3610-3615.
5. Boven E, Schippe H, Erkelens CA, Hatty SA, Pinedo HM. 1993. The influence of schedule and the dose of gemcitabine on the anti-tumor efficacy in experimental human cancer. British Journal of Cancer BJC 68:52-56.
6. Cheson BD, Keating MJ, Plunkett W. 1997. Nucleoside analogs in cancer therapy. New York: Marcel Dekker, Inc., ISBN 0-8247-9850-3.
7. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK. 2006. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Research 66(2):981-988.
8. Dahlberg WK, Little JB. 1992. Differential sensitization of human tumor cells by Ara-A to X-irradiation and its relationship to inherent radioresponse. Radiation Research 130:303-308.
9. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. 1997. Cell neurobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 27:1-20.
10. Elshaikh M, Hunter N, Milas L, Hittelman WN, Ang KK, Mason K. 1997. Time dependent modulation of jejunal radioresponse with gemcitabine. Proceedings of the 45th Annual Meeting of radiation Research Society, Chicago, USA. A528.
11. Facchinetti A, Tessarollo L, Mazzocchi M, Kingston R, Collavo D, Biasi G. 1991. An improved method for detection of DNA fragmentation. Journal of Immunological Methods 136:125-131.
12. Fertil B, Dertinger H, Courdi A, Malaise EP. 1984. Mean inactivation dose: A useful concept for intercomparison of human cell survival curves. Radiation Research 99:73-84.
13. Fujii T, Hunter N, Elshaikh M, Hittelmann WN, Plunkett W, Ang KK, Milas L. 1997. Gemcitabine improves the therapeutic ratio of radiotherapy in mouse tumours after single dose irradiation. Proceedings of the 45th Annual Meeting of the Radiation Research Society, Chicago, USA. A529.
14. Grégoire V, Hunter N, Brock W, Milas L, Plunkett W, Hittelman WN. 1994a. Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single dose irradiation. International Journal of Radiation Oncology Biology Physics 30:363-371.
15. Grégoire V, Hunter N, Milas L, Brock WA, Plunkett W, Hittelman WN. 1994b. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Research 54:468-474.
16. Grégoire V, Van NT, Stephens C. 1994c. The role of fludarabine-induced apoptosis and cell cycle synchronisation in enhanced murine tumor radiation response in vivo. Cancer Research 54(23):6201-6209.
17. Grégoire V, Ruifrok AC, Price RE, Brock WA, Hittelmann WN, Plunkett WK, Ang KK. 1995. Effect of intra-peritoneal Fludarabine on rat spinal cord tolerance to fractionated irradiation. Radiotherapy and Oncology 36:50-55.
18. Grégoire V, Hittelmann WN. 1997. Nucleoside analogs as radiosensitizing agents. In: Cheson BD, Keating MJ, Plunkett W, editors. Nucleoside analogues in Cancer therapy. New York: Marcel Dekker. pp 315-358.
19. Grégoire V, Debast M, Rosier JF, Beauduin M, Bruniaux M, Decoster B, Scalliet P. 1998a. Relationship between deoxycytidine kinase (cdk) activity and dck over deoxycytidine deaminase activity ratio, and radiosensitization by fludarabine and gemcitabine. Proceedings of American association for Cancer Research 39. A2597.
20. Grégoire V, Beauduin M, Bruniaux M, De Coster B, Octave Prignot M, Scalliet P. 1998b. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction of a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. International Journal of Radiation Biology 73:511-520.
21. Grégoire V, Hittelmann WN, Rosier JF, Milas L. 1999. Chemoradiotherapy: Radiosensitizing nucleoside analogues (Review). Oncology Reports 6:949-957.
22. Grégoire V, Ang KK, Rosier JF, Beaudin M, Garden AS, Hamoir M, Hittelmann WN, Humblet Y, Khuri FR, Milas L, Mitine C, Scalliet P. 2002. A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamos cell carcinoma. Radiotherapy and Oncology 63(2):187-193.
23. Heinemann V, Schulz L, Issels RD, Plunkett W. 1995. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism. Seminars in Oncology 22:11-18.
24. Hertel L, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB. 1990. Evaluation of the antitumor activity of gemcitabine (2′2′- difluoro-2′deoxycitidine). Cancer Research 50:4417-4422.
25. Huang P, Chubb S, Plunkett W. 1990. Termination of DNA synthesis by 9-ß-D-arabinofuranosyl-2-Fluoroadenine: A mechanism for cytotoxicity. Journal of Biological Chemistry 265:16617-16625.
26. Iwasaki H, Huang P, Keating MJ, Plunkett W. 1997. Differential incorporation of ara-c, gemcitabine, andfludarabine into replicating and repairing DNA in proliferating human leukaemia cells. Blood 90:270-278.
27. Jayanth RV, Hittelman WN. 1991. 9-ß-D-arabinofuranosyl-2- Fluoroadenine inhibits both the slow and fast components of chromosome repair (abstract). In: Chapman JD, Dewey WC, Whitemore GF, editors. Radiation research: A 20th century perspective. San Diego, CA: Academic Press. pp 411.
28. Johnson S, Smith AG, Löffler H, Ösby E, Juliusson G, Emmerich B, Wyld P, Hiddemann W, The French Cooperative Group. 1996. Multicentre prospektive randomised trial of fludarabine versus cyclophosphamid, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347:1432-1438.
29. Joschko MA, Webster LK, Groves J, Yuen K, Palatsides M, Ball DL, Millward MJ. 1997. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiation Oncology Investigations 5:62-71.
30. Keating MJ, Kantarjian H, Talpaz M, Redmann J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB. 1989. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25.
31. Kim JH, Alfieri A, Kim SH, Fuks Z. 1986. The potentiation of radiation response on murine tumor by Fludarabine phosphate. Cancer Letters 31:69-76.
32. Lathan B, Diehl V, Clark GM, von Hoff DD. 1988. Cytotoxic activity of 9-ß-D-arabinofuranosyl-2-Fluoroadenine-5-monophosphate (Fludarabine) in a human tumor cloning system. European Journal of Cancer and Clinical Oncology 24:1891-1895.
33. Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ. 1998. Radiosensitizing potential of gemcitabine (2′,2′-difluoro- 2′deoxycitidine) within the cell cycle in vitro. International Journal of Radiation Oncology Biology Physics 41:875-882.
34. Laurent D, Pradier O, Schmidberger H, Rave-Fränk M, Frankenberg D, Hess CF. 1998. Radiation rendered more cytotoxic by Fludarabine monophosphate in a human oropharynx carcinoma cell-line than in fetal lung Fibroblasts. Journal of Cancer Research and Clinical Oncology 124:485-492.
35. Lawrence TS, Chang E, Hahn TM, Hertel LW, Shewach DS. 1996. Radiosensitization of pancreatic cancer cells by 2′-2′ difluoro-2′ deoxycytidine. International Journal of Radiation Oncology Biology Physics 41:867-872.
36. Lawrence TS, Chang E, Hahn TM, Shewach DS. 1997. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′-2′ deoxycyitidine (Gemcitabine). Clinical Cancer Research 3:777-782.
37. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE. 1998. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines, Cancer Research 58:4349-4357.
38. Malaise EP, Debieu D, Chavaudra N, Grinfeld S. 1989. The effect of the oxic cell sensitizer b-Ara-A on human fibroblasts in plateau and in exponential growth phases. International Journal of Radiation Oncology Biology Physics 16:1257-1259.
39. Milas L, Fuji T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang KK, Hittelman W. 1999. Enhancement of tumor radio-response in vivo by gemcitabine. Cancer Research 59:107-114.
40. Milano MT, Haraf DJ, Stenson KM, Witt ME, Eng C, Mittal BB, Argiris A, Pelzer H, Kozloff MF, Vokes EE. 2004. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor prognosis cancer of the head and neck. Clinical Cancer Research 10(15):4922-4932.
41. Milano MT, Vokes EE, Salama JK, Stenson KM, Kao J, Witt ME, Mittal BB, Argiris A, Weichselbaum RR, Haraf DJ. 2005. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. International Journal of Radiation Oncology Biology Physics 61(4):1095-1106.
42. Mittelmann A, Ashikari R, Ahmed T, Savona S, Arnold P, Arlin Z. 1988. Phase II trial of fludarabine phosphate (f-ara-AMP) in patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology 22:63-64.
43. Mose S, Class R, Weber HW, Oszwald A, Rahn A, Brady LW, Böttcher HD. 2001. Komnination von Radiotherapie und Gemcitabine. Strahlentherapie und Onkologie 178:59-70.
44. Mose S, Karapetian M, Jüling-Pohlit L, Taborski B, Ramm U, Damrau M, Rahn A, Böttcher HD. 1999. The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine. Strahlentherapie Onkologie 175:78-83.
45. Mose S, Karapetian M, Jüling-Pohlit L, Taborski B, Damrau M, Ramm U, Rahn A, Böttcher HD. 2000. Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. Anticancer Research 20:401-405.
46. Mullen J, Xu YZ, Lepek K, Plunkett W, Rich T. 1994. Cytotoxicity and radiosensitization by gemcitabine in exponential human colon adenocarcinoma cells. Proceedings of the 42nd Annual meeting of the radiation Research Society, Nashville, TE, USA. A 206.
47. Pauwels B, Korst AEC, Lardon F, Vermorken JB. 2005. Combined modality therapy of gemcitabine and radiation. Oncologist 10(1):34-51.
48. Pauwels B, Korst AEC, Lambrechts HAJ, Pattyn GGO, Lardon F, Vermorken JB. 2006. The radiosensitizing effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemotherapy and Pharmacology 58:219-228.
49. Plunkett W, Ghandi V, Chubb S, Nowak B, Heinemann V, Mineishi S, Sen A, Hertel LW, Grindey GB. 1989. 2′,2′-difluoro-deoxycytidine metabolism and mechanism of action in human leukaemia cells. Nucleosides Nucleotides Nucleic Acids 8:775-785.
50. Plunkett W, Huang P, Ghandi V. 1995. Preclinical characteristics of gemcitabine. Anticancer Drugs 6:7-13.
51. Plunkett W, Chubb S, Alexander L, Montgomery J. 1980. Comparison of the toxicity and metabolism of 9-ß-D-arabinofuranosyl-2-Fluoroadenine and 9-ß-D-arabinofuransyladenine in human lymphoblastoid cells. Cancer Research 40:2349-2355.
52. Plunkett W, Huang P, Ghandi V. 1990. Metabolism and action of Fludarabine phosphate. Seminars in Oncology (Suppl. 8):3-17.
53. Plunkett W, Ghandi V, Huang P, Robertson LE, Yang LY, Grégoire V, Estey E, Keating MJ. 1993. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Seminars in Oncology 20(Suppl. 7):2-12.
54. Rave-Fränk M, Virsik-Peuckert P, Bertram K, Schmidberger H. 1996. Chromosome analysis in X-irradiated primary cells of a human squamous cell carcinoma by fluorescence in situ hybridization. International Journal of Radiation Biology 69:695-700.
55. Rockwell S, Grindey GB. 1992. Effect of 2′- 2′difluorodeoxycitidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncology Research 4:151-155.
56. Rosier JF, Michaux L, Ameye G, Cedervall B, Libouton JM, Octave-Prignot M, Verellen-Dumoulin C, Scalliet P, Grégoire V. 2003. The radioenhancement of two human head and neck squamous cell carcinomas by 2′-2′ difluorodeoxycytidine (gemcitabine; dFdC) is mediated by an increase in radiation-induced residual chromosome aberrations but not residual DNA DSBs. Mutation Research 19(1-2):15-26.
57. Ruiz van Haperen VWT, Veerman G, Boven E, Noorhuis P, Vermoken JB, Peters GJ. 1994. Schedule dependence of sensitivity to 2′2′- difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tulour cell lines and solid tumours. Biochemical Pharmacology 48:1327-1339.
58. Scalliet P, Goor C, Galdermans D, van Meebeek J, Groen HJM, van der Leest AHD, Westerink H, Jungnelius U, Turrisi A. 1998. Gemzar (Gemzitabine) with thoracic radiotherapy - a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Proceedings of The American Society of Clinical Oncology (ASCO) 17:A1923.
59. Shewach DA, Hahn TM, Chang E, Hertel HW, Lawrence TS. 1994. Metabolism of 2′-2′ difluoro-2′deoxycitidine and radiation sensitization of human colon carcinoma cells. Cancer Research 54:3218-3223.
60. Shewach DS, Lawrence TS. 1995. Radiosensitization of human tumor cells by gemcitabine in vitro. Seminars in Oncology 22:68-71.
61. Spriggs D, Robbins G, Mitchell T, Kufe D. 1986. Incorporation of 9-ß-D-arabinofuranosyl-2-Fluoroadenine into HL-60 cellular RNA and DNA. Biochemical Pharmacology 35:247-252.
62. Spector DL, Goldman RD, Leinwand LA. 1998. Culture and biochemical analysis of cells. Cell: A laboratory manual. Vol. 1. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1998. pp 156.
63. Steel GG. 1979. Terminology in the description of drug-radiation interactions. International Journal of Radiation Oncology Biology Physics 5:1145-1150.
64. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Capuzzo F. 2005. Role of gemcitabine in cancer therapy. Future Oncology 1(1):7-17.
65. Weiss GB, Metch B, von Hof DD, Taylor SA, Saiers JH. 1987. Phase II trial of fludarabine phosophate in patients with head and neck cancer. A southwest oncology group study. Cancer Treatment Report 71:1313-1314.